The research will be presented at the 2025 american society of clinical oncology (asco) annual meeting. Carboplatin + etoposide + atezolizumab (tecentriq®) has info patients should know about Read, listen, and watch videos about side effects from carboplatin + etoposide + atezolizumab (tecentriq®) for small cell lung cancer In a clinical trial of patients with advanced small cell lung cancer (sclc), atezolizumab (tecentriq), combined with standard chemotherapy, modestly increased survival—the first trial in more than 20 years to show a survival improvement in this cancer.
OPEN
